207 related articles for article (PubMed ID: 36289063)
1. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
Kolwelter J; Kannenkeril D; Linz P; Jung S; Nagel AM; Bosch A; Ott C; Bramlage P; Nöh L; Schiffer M; Uder M; Achenbach S; Schmieder RE
Clin Res Cardiol; 2023 Jan; 112(1):134-144. PubMed ID: 36289063
[TBL] [Abstract][Full Text] [Related]
2. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
3. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Pietschner R; Kolwelter J; Bosch A; Striepe K; Jung S; Kannenkeril D; Ott C; Schiffer M; Achenbach S; Schmieder RE
Cardiovasc Diabetol; 2021 Nov; 20(1):219. PubMed ID: 34753480
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
5. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
6. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
8. Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial.
Prochaska JH; Jünger C; Schulz A; Arnold N; Müller F; Heidorn MW; Baumkötter R; Zahn D; Koeck T; Tröbs SO; Lackner KJ; Daiber A; Binder H; Shah SJ; Gori T; Münzel T; Wild PS
Clin Res Cardiol; 2023 Jul; 112(7):911-922. PubMed ID: 36763159
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Burkhoff D; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
Circ Heart Fail; 2022 Mar; 15(3):e009156. PubMed ID: 34743533
[TBL] [Abstract][Full Text] [Related]
11. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.
Kolwelter J; Bosch A; Jung S; Stabel L; Kannenkeril D; Ott C; Bramlage P; Schiffer M; Achenbach S; Schmieder RE
ESC Heart Fail; 2021 Dec; 8(6):5327-5337. PubMed ID: 34544205
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
17. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Omar M; Jensen J; Kistorp C; Højlund K; Videbæk L; Tuxen C; Larsen JH; Andersen CF; Gustafsson F; Køber L; Schou M; Møller JE
Cardiovasc Diabetol; 2022 Feb; 21(1):34. PubMed ID: 35219331
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
20. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Refardt J; Imber C; Nobbenhuis R; Sailer CO; Haslbauer A; Monnerat S; Bathelt C; Vogt DR; Berres M; Winzeler B; Bridenbaugh SA; Christ-Crain M
J Am Soc Nephrol; 2023 Feb; 34(2):322-332. PubMed ID: 36396331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]